Abstract
Abstract Periostin (PN), an extracellular matrix protein, is reported to be overexpressed in a variety of human cancers and its functions appear to be linked to tumor angiogenesis and metastasis. Our previous results show that engineered PN overexpression promotes ovarian tumor growth and dissemination in vivo. In the present study, we developed a neutralizing monoclonal antibody to PN, named MZ-1, and have investigated its effects on human ovarian tumor cell metastasis and progression. MZ-1 markedly reduced tumor metastatic growth in orthotopic ovarian tumor models derived from two PN-expressing ovarian cancer cell lines A2780 and TOV-112D. These in vivo antitumor effects of MZ-1 were attributed to its specific inhibition of anchorage-independent growth and survival of PN-expressing cells, as well as its neutralization on PN-induced migration. The data suggests that blocking PN expression may be a novel approach for treatment of ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4407.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
